Literature DB >> 16980011

MELD score as a prognostic model for listing acute liver failure patients for liver transplantation.

M B Zaman1, E Hoti, A Qasim, D Maguire, P A McCormick, J E Hegarty, J G Geoghegan, O Traynor.   

Abstract

OBJECTIVES: The King's College Hospital (KCH) criteria are widely used for listing patients with acute liver failure (ALF) for liver transplantation (LT). Recent reports have suggested that the Model for End-Stage Liver Disease (MELD) score may be useful in assessing prognosis in ALF (nonparacetamol). This study compares prognostic accuracy of the two systems in patients with paracetamol (POD)-induced ALF treated in this unit.
METHODS: Seventy-two patients (average age 38 years; F:M ratio 2:1) admitted from 1994 to 2005 with POD-related ALF were studied. Clinical and biochemical parameters were recorded. The effect of applying a MELD score of greater than 30 as listing criteria for LT was calculated and compared with the KCH criteria. Outcomes were defined as LT, death, or full recovery.
RESULTS: Thirty-one patients (43%) recovered with medical therapy, 29 (40%) patients died, and 12 (17%) underwent LT. Sixty five percent of patients had a MELD > 30 and therefore could potentially be listed on admission; however, using KCH criteria only 24% patients were listed immediately. Sensitivity and negative predictive value of MELD was higher then KCH; however, we found KCH to have much higher specificity and positive predictive value.
CONCLUSION: MELD has higher sensitivity and negative predictive value for POD-induced ALF than the KCH criteria. However, the high false-positive rate associated with MELD limits its clinical utility. The high negative predictive value of MELD score may allow it to be used in conjunction with KCH criteria to avoid unneeded LT in patients who will likely recover spontaneously.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980011     DOI: 10.1016/j.transproceed.2006.06.004

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  Liver transplantation for hepatocellular carcinoma in Ireland: Pre-operative alpha-fetoprotein predicts tumour recurrence in a 14-year single-centre national experience.

Authors:  Donal B O'Connor; John P Burke; John Hegarty; Aiden P McCormick; Niamh Nolan; Emir Hoti; Donal Maguire; Justin Geoghegan; Oscar Traynor
Journal:  World J Transplant       Date:  2016-06-24

2.  Development of a Model to Predict Transplant-free Survival of Patients With Acute Liver Failure.

Authors:  David G Koch; Holly Tillman; Valerie Durkalski; William M Lee; Adrian Reuben
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-13       Impact factor: 11.382

3.  Short-term efficacy of treating hepatitis B virus-related acute-on-chronic liver failure based on cold pattern differentiation with hot herbs: A randomized controlled trial.

Authors:  Yu-Ming Guo; Feng-Yi Li; Man Gong; Lin Zhang; Jia-Bo Wang; Xiao-He Xiao; Jun Li; Yan-Ling Zhao; Li-Fu Wang; Xiao-Feng Zhang
Journal:  Chin J Integr Med       Date:  2016-05-24       Impact factor: 1.978

Review 4.  Acute liver failure and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2013-08

Review 5.  Recent developments in acute liver failure.

Authors:  William M Lee
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-02       Impact factor: 3.043

6.  Evaluation of a scoring system for assessing prognosis in pediatric acute liver failure.

Authors:  Brandy R Lu; Jane Gralla; Edwin Liu; Emily L Dobyns; Michael R Narkewicz; Ronald J Sokol
Journal:  Clin Gastroenterol Hepatol       Date:  2008-10       Impact factor: 11.382

7.  Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure.

Authors:  William M Lee; Linda S Hynan; Lorenzo Rossaro; Robert J Fontana; R Todd Stravitz; Anne M Larson; Timothy J Davern; Natalie G Murray; Timothy McCashland; Joan S Reisch; Patricia R Robuck
Journal:  Gastroenterology       Date:  2009-06-12       Impact factor: 22.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.